Zicix (OTCMKTS:ZICX – Get Rating) and Invitae (NYSE:NVTA – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, earnings, profitability, dividends and valuation.
Analyst Ratings
This is a breakdown of current ratings and recommmendations for Zicix and Invitae, as reported by MarketBeat.
Get Zicix alerts:| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Zicix | 0 | 0 | 0 | 0 | N/A |
| Invitae | 3 | 9 | 0 | 0 | 1.75 |
Invitae has a consensus price target of $8.04, suggesting a potential upside of 168.10%. Given Invitae's higher probable upside, analysts clearly believe Invitae is more favorable than Zicix.
Volatility & Risk
Zicix has a beta of 0.75, suggesting that its share price is 25% less volatile than the S&P 500. Comparatively, Invitae has a beta of 1.59, suggesting that its share price is 59% more volatile than the S&P 500.Earnings & Valuation
This table compares Zicix and Invitae's gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Zicix | N/A | N/A | N/A | N/A | N/A |
| Invitae | $460.45 million | 1.58 | -$379.01 million | ($13.84) | -0.22 |
Zicix has higher earnings, but lower revenue than Invitae.
Insider and Institutional Ownership
88.3% of Invitae shares are held by institutional investors. 1.1% of Invitae shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares Zicix and Invitae's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Zicix | N/A | N/A | N/A |
| Invitae | -617.65% | -39.04% | -17.75% |
Summary
Invitae beats Zicix on 5 of the 8 factors compared between the two stocks.
About Zicix
(Get Rating)
Zicix Corporation, through its subsidiary, Texas Mobile Health, Inc., provides diagnostic medical imaging services in Houston, Texas. It offers cardiac diagnostic services, including echocardiogram, stress testing, carotid ultrasound, and halter and event monitoring services; medical services, such as general medical care, medical care for home health patients, general and immigration physicals, weight reduction, cold laser pain relief treatment, physical therapy, and anti-aging treatment; and MRI, CT, and X-Ray services. The company was formerly known as Bederra Corporation and changed its name to Zicix Corporation on February 8, 2011. Zicix Corporation was founded in 1979 and is based in Houston, Texas.
About Invitae
(Get Rating)
Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.
Receive News & Ratings for Zicix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zicix and related companies with MarketBeat.com's FREE daily email newsletter.